Barclays analyst Peter Warendorf initiated coverage of HealthEquity (HQY) with an Overweight rating and $118 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity Inc. Reports Strong Q3 Earnings and Growth
- HealthEquity price target raised to $120 from $117 at Deutsche Bank
- HealthEquity’s Strong Q3 Performance and Raised Guidance Justify Buy Rating with Significant Upside Potential
- Balanced Outlook for Healthequity Amid Strong Performance and Economic Uncertainty Justifies Hold Rating
- HealthEquity price target raised to $129 from $126 at JPMorgan